Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Albireo Pharma, Inc. (NASDAQ: ALBO).

Full DD Report for ALBO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALBO)

Albireo Pharma's (ALBO) CEO Ron Cooper on Q1 2018 Results - Earnings Call Transcript
Albireo Pharma, Inc. (ALBO) Q1 2018 Earnings Conference Call May 17, 2018 08:30 A.M. ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Paresh Soni - Chief Medical Officer Analysts Ritu Baral - Cowen and Company Unidentified An...
Source: SeekingAlpha
Date: May, 17 2018 12:13
Albireo Pharma EPS of -$0.15
Albireo Pharma (NASDAQ: ALBO ): Q1 EPS of -$0.15 may not be comparable to consensus of $1.77. More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 07:36
Albireo Provides First Quarter 2018 Business Update
 First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC   Elobixibat in Japan becomes first IBAT inhibitor approved in the world   Management to host conference call and webcast today at 8:30 a.m. EDT  BOSTON, May 17, 2018 (GLOBE NE...
Source: GlobeNewswire
Date: May, 17 2018 07:30
Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250
— Pivotal program in rare and life-threatening pediatric liver disorder underway — — Data intended to provide support for anticipated drug approval applications in US and EU — BOSTON, May 16, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasda...
Source: GlobeNewswire
Date: May, 16 2018 08:30
Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, May 17...
Source: GlobeNewswire
Date: May, 09 2018 08:00
Albireo to Present at Deutsche Bank 43rd Annual Health Care Conference
BOSTON, April 30, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Deutsche ...
Source: GlobeNewswire
Date: April, 30 2018 08:00
Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that findings from two studies that deepen the understanding of cholestatic liver disease will be pre...
Source: GlobeNewswire
Date: April, 19 2018 08:00
Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The International Liver Congress(TM) 2018
— Correlation observed between reduction in serum bile acids and autotaxin with A4250 — — Autotaxin has potential to be important biomarker of cholestatic pruritus — BOSTON, April 14, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO),...
Source: GlobeNewswire
Date: April, 14 2018 08:00
Biotech Forum: The Week Ahead
It has always seemed that a fear of judgment is the mark of guilt and the burden of insecurity. ” ― Criss Jami, Killosophy Markets plunged Friday in reaction to escalating trade tensions between the U.S. and China. The major indices ended up again in the red last week. The...
Source: SeekingAlpha
Date: April, 09 2018 10:38
Albireo to Present at H.C. Wainwright Global Life Sciences Conference
BOSTON, April 02, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwrigh...
Source: GlobeNewswire
Date: April, 02 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1733.8032.8233.9031.8668,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-203,4539,18937.5775Short
2018-08-174,9506,89471.8016Short
2018-08-168,57519,87443.1468Short
2018-08-157,68414,43153.2465Short
2018-08-1410,86518,60858.3889Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALBO.


About Albireo Pharma, Inc. (NASDAQ: ALBO)

Logo for Albireo Pharma, Inc. (NASDAQ: ALBO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $367,026,954 - 05/14/2018
  • Issue and Outstanding: 11,897,146 - 03/01/2018

 


Recent Filings from (NASDAQ: ALBO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: ALBO)

Daily Technical Chart for (NASDAQ: ALBO)


Stay tuned for daily updates and more on (NASDAQ: ALBO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALBO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALBO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALBO and does not buy, sell, or trade any shares of ALBO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/